PLCSF – .09 Medical Device Alert- Clinical Trials In The U.S.
SecretStockPromo Newsletter
My new “Bullish” pick is: PLCSF
SSP Subscribers,
I Am Issuing An Immediate Alert on PLC Medical Systems (PLCSF).
PLCSF is a small medical device that we believe could see a breakout in the coming sessions after several recent developments are beginning to capture the attention of investment community.
Let us explain why PLCSF is NOT your typical OTC Company:
PLCSF is already seeing major rev growth in Europe and is in the process of breaking into the U.S. market with its primary product, as the company is now in clinical trials in the United States.
PLCSF has been selling RenalGuard® in Europe for several years already and has received full FDA Approval for pivotal trials in the United States.
PLCSF has now seen 3 years of increasing rev (from 2010 to 2012), with 2012 fiscal year revs reaching over $1M.
PLCSF has a strong patent portfolio in place, and a compelling ‘first mover’ advantage as RenalGuard® is gaining market share in Europe. The company is now focused on brining RenalGuard® to the U.S. in hopes to receive full FDA approval to begin selling their revolutionary product in the United States.
This is a company that did over 1M in rev in 2012, and yet has an extremely low float. In fact at the current price, the company has an unbelievably tiny market cap of just over 5M.
With increasing year-over-year revs, strong growth in Europe, and the prospect of FDA approval in the United States, this could be an unbelievable year ahead for PLCSF.
Considering the small market cap as well as the strong potential for expansion in the United States, PLCSF could be on track for a breakout 2013.
Begin your research right away and lets be ready for PLCSF on Thursday as investor awareness on PLCSF is increasing steadily. With such a low float, PLCSF could move quickly in the coming sessions.
About PLC Systems Inc.
Headquartered in Milford, Mass., PLC Systems Inc. is a medical device company focused on innovative technologies for the cardiac and vascular markets. PLC`s newest product, RenalGuard, has been developed to rapidly remove contrast dyes that are potentially toxic to patients undergoing certain cardiac and vascular imaging procedures. The Product is CE-marked and is being marketed in Europe and selected countries around the world. Two investigator-sponsored European studies have demonstrated RenalGuard`s effectiveness at preventing Contrast-Induced Acute Kidney Injury (CI-AKI). RenalGuard is being studied in a pivotal trial in the U.S., as part of the FDA approval process.
PLC Systems Inc. Receives Key U.S. Method Patent for RenalGuard®
Just last month on June 6, 2013, PLCSF announced it has been granted a new method patent by the U..S Patent and Trademark Office entitled, “Patient Hydration Method.” The patent claims cover the use of RenalGuard Therapy® and the RenalGuard® device to protect patients` kidneys from therapeutic agents that are potentially toxic to the kidney, such as those used in the treatment of cancer or serious infections. This patent greatly expands PLC`s intellectual property position. The company`s existing core patents cover the use of the RenalGuard technology to reduce the risk of Acute Kidney Injury (AKI) from exposure to contrast agents, which specifically lead to Contrast-Induced Acute Kidney Injury or CI-AKI.
Technical Indicators:
PLCSF looks to be on the verge of a significant breakout move up the charts, with a number of technical indicators showing bullish trends developing for the near term.
Examining the 20-Day Bollinger Bands, price has channeled away from the mean and between the upper bands or the “buy zone”.
Looking at the 10-8 Day Moving Average Hilo Channel, the past two consecutive bars have traded above and completely outside the channel also triggering a “buy” action.
The 20-Day Moving Average vs. Price chart indicates momentum building in the near term, and the 7-Day Average Directional Indicator is showing upward directional movement, evidenced by the recent reversal as PLCSF bounced off levels just below 9-cents this past June to close at 11-cents per share in the previous session.
Already showing upward movement, with a 52 Week High of 30-cents, at current levels, PLCSF remains well below its historic highs to show enormous potential upside in the sessions ahead.
PLCSF has shown consistent growth in both annual rev and gross profit for the past 3 years, and topping over 1M in total rev for its latest complete fiscal year ending December of 2012.
PLCSF could see significant movement in the sessions ahead driven increased media attention surrounding clinical trials and the continued expansion of its patent portfolio.
With a solid track record for year-over-year growth, PLCSF could see even more rapid and substantial growth as it seeks to expand into the U.S. markets.
As always, please do your own research this evening, and keep an eye on PLCSF throughout the week.
Happy Trading! SecretStockPromo
Disclaimer:
This is a Paid Advertisement for the company or companies mentioned in this publication. Do not base any investment decision upon any of the materials found in this publication or on our Web site.
The information contained on our website or in any of our newsletters should be viewed as a commercial advertisement and is not intended to be investment advice. Our Web site and our newsletter are services of Galaxy LLC., a media and advertising firm that is compensated by the companies profiled on our web site or in our newsletter. All direct and third party compensation received has been disclosed on our newsletter and/or our website in accordance with section 1 7 ( b ) of the Securities Act of 1 9 3 3.
Compensation: We have been compensated Thirty Thousand Dollars by a third party, TSX Ventures, LLC. regarding PLC Systems, Inc. for this publication. We do not own any shares of PLCSF.
This message was sent to from:
Secret Stock Promo | Galaxy, LLC | 22431 Antonio Parkway, Suite B160-258 | Rancho Santa Margarita, CA 92688
Related posts:
- **PLCSF** looks ready to fly. Medical innovator with a lock on its industry.
- PLCSF Coughed Up 8% gains – But I Want More! New Alert In The Morning.
- PLCSF is about to go nuts! Read inside.
- Reminder, PLCSF is my alert today!
- PLCSF’s Q1 revenue rises as sales of lead product increase